Literature DB >> 28065804

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Chaturaka Rodrigo1, Melanie R Walker2, Preston Leung2, Auda A Eltahla2, Jason Grebely3, Gregory J Dore3, Tanya Applegate3, Kimberly Page4, Sunita Dwivedi4, Julie Bruneau5, Meghan D Morris6, Andrea L Cox7, William Osburn7, Arthur Y Kim8, Janke Schinkel9, Naglaa H Shoukry5, Georg M Lauer8, Lisa Maher3, Margaret Hellard10, Maria Prins11, Fabio Luciani2, Andrew R Lloyd12, Rowena A Bull2.   

Abstract

Broadly neutralizing antibodies have been associated with spontaneous clearance of the hepatitis C infection as well as viral persistence by immune escape. Further study of neutralizing antibody epitopes is needed to unravel pathways of resistance to virus neutralization, and to identify conserved regions for vaccine design. All reported broadly neutralizing antibody (BNAb) epitopes in the HCV Envelope (E2) glycoprotein were identified. The critical contact residues of these epitopes were mapped onto the linear E2 sequence. All publicly available E2 sequences were then downloaded and the contact residues within the BNAb epitopes were assessed for the level of conservation, as well as the frequency of occurrence of experimentally-proven resistance mutations. Epitopes were also compared between two sequence datasets obtained from samples collected at well-defined time points from acute (<180days) and chronic (>180days) infections, to identify any significant differences in residue usage. The contact residues for all BNAbs were contained within 3 linear regions of the E2 protein sequence. An analysis of 1749 full length E2 sequences from public databases showed that only 10 out of 29 experimentally-proven resistance mutations were present at a frequency >5%. Comparison of subtype 1a viral sequences obtained from samples collected during acute or chronic infection revealed significant differences at positions 610 and 655 with changes in residue (p<0.05), and at position 422 (p<0.001) with a significant difference in variability (entropy). The majority of experimentally-described escape variants do not occur frequently in nature. The observed differences between acute and chronically isolated sequences suggest constraints on residue usage early in infection.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Broadly neutralizing antibodies; Epitopes; Glycoprotein E2; Hepatitis C; InC(3) collaborative

Mesh:

Substances:

Year:  2017        PMID: 28065804      PMCID: PMC5330849          DOI: 10.1016/j.meegid.2017.01.006

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  58 in total

1.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Authors:  Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

4.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Dhanya Jayaraj; Richard J P Brown; Timothy P Hickling; William L Irving; Arvind H Patel; Jonathan K Ball
Journal:  J Gen Virol       Date:  2007-11       Impact factor: 3.891

Review 6.  Neutralizing antibody response to hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Steven K H Foung
Journal:  Viruses       Date:  2011-11-02       Impact factor: 5.048

7.  Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment.

Authors:  Nicholas C Wu; Yushen Du; Shuai Le; Arthur P Young; Tian-Hao Zhang; Yuanyuan Wang; Jian Zhou; Janice M Yoshizawa; Ling Dong; Xinmin Li; Ting-Ting Wu; Ren Sun
Journal:  BMC Genomics       Date:  2016-01-12       Impact factor: 3.969

8.  Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Authors:  Zhen-Yong Keck; Jinming Xia; Zhaohui Cai; Ta-Kai Li; Ania M Owsianka; Arvind H Patel; Guangxiang Luo; Steven K H Foung
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Judith M Timms; C Patrick McClure; Richard J P Brown; Timothy P Hickling; Thomas Pietschmann; Ralf Bartenschlager; Arvind H Patel; Jonathan K Ball
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

Review 10.  Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.

Authors:  Giuseppe Sautto; Alexander W Tarr; Nicasio Mancini; Massimo Clementi
Journal:  Clin Dev Immunol       Date:  2013-07-09
View more
  5 in total

1.  A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.

Authors:  Yan Q Xiong; Angeles Estellés; L Li; W Abdelhady; R Gonzales; Arnold S Bayer; Edgar Tenorio; Anton Leighton; Stefan Ryser; Lawrence M Kauvar
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 2.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

Review 3.  Defining Breadth of Hepatitis C Virus Neutralization.

Authors:  Valerie J Kinchen; Justin R Bailey
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

4.  A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.

Authors:  Janelle Johnson; Holly Freedman; Michael Logan; Jason Alexander Ji-Xhin Wong; Darren Hockman; Chao Chen; Jianqi He; Michael R Beard; Nicholas S Eyre; Thomas F Baumert; D Lorne Tyrrell; John L M Law; Michael Houghton
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies.

Authors:  Melanie R Walker; Preston Leung; Auda A Eltahla; Alexander Underwood; Arunasingam Abayasingam; Nicholas A Brasher; Hui Li; Bing-Ru Wu; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.